Alnylam Pharmaceuticals Inc to Discuss Full Results from ILLUMINATE-A Phase 3 Study of Lumasiran at ERA-EDTA International Congress Transcript
Ladies and gentlemen, thank you for standing by. Welcome to the Alnylam Pharmaceuticals conference call to discuss results from the ILLUMINATE-A Phase III study. There will be a question-and-answer session to follow. Please be advised that this call is being taped at the company's request.
I would now like to turn the call over to the company.
Good morning. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today are John Maraganore, our Chief Executive Officer; Akshay Vaishnaw, our President of R&D; and Barry Greene, our President. Also joining us and available for Q&A are Yvonne Greenstreet, our Chief Operating Officer; Pushkal Garg, our Chief Medical Officer; and Pritesh Gandhi, General Manager of the Lumasiran Program. For those of you participating via conference call, the slides will be made available via webcast and also be accessed by going to the Investors page of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
